fluorouracil has been researched along with Esophageal Stenosis in 16 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Esophageal Stenosis: A stricture of the ESOPHAGUS. Most are acquired but can be congenital.
Excerpt | Relevance | Reference |
---|---|---|
"Malignant esophageal stenosis is a common and severe complication of advanced esophageal cancer that can be a serious problem in the continuation of chemotherapy and other anticancer treatments." | 5.91 | Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis. ( Inaki, N; Kinoshita, J; Moriyama, H; Nakamura, K; Okamoto, K; Saito, H; Shimada, M; Tsuji, T; Yamaguchi, T, 2023) |
"These studies demonstrate that the concurrent addition of modest dose cisplatin and infusional dose fluorouracil to radiation in the definitive, preoperative, and palliative settings contribute to high rates of durable dysphagia-free survival, with overall survival comparable to (and possibly better than) the chemoradiation arm of the recently reported Intergroup Study, but at the cost of less morbidity." | 5.08 | Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. ( Ackland, SP; Burmeister, BH; Denham, JW; Devitt, P; Gill, PG; Hamilton, CS; Jamieson, GG; Lamb, DS; O'Brien, M; Yeoh, E, 1995) |
" Here, we report the case of a successfully treated patient with thoracic esophageal cancer who had esophageal perforation during docetaxel, cisplatin, and 5-fluorouracil chemotherapy." | 3.91 | Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy. ( Doki, Y; Kobayashi, T; Makino, T; Mori, M; Tanaka, K; Yamasaki, M, 2019) |
"Esophageal stenosis was identified as a candidate stratification factor for randomized trials of unresectable LAESCC patients." | 2.84 | Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). ( Ando, N; Fukuda, H; Igaki, H; Ishikura, S; Katayama, H; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kitagawa, Y; Kojima, T; Kosugi, S; Nakamura, K; Okabe, H; Okuno, T; Shinoda, M; Toh, Y; Tsubosa, Y; Wakabayashi, M, 2017) |
"Esophageal stenosis was the only significant risk factor for esophageal fistula formation both in univariate (P = 0." | 2.82 | Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303. ( Fukuda, H; Honma, Y; Igaki, H; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Shinoda, M; Sudo, K; Tsubosa, Y; Tsushima, T, 2016) |
"Malignant esophageal stenosis is a common and severe complication of advanced esophageal cancer that can be a serious problem in the continuation of chemotherapy and other anticancer treatments." | 1.91 | Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis. ( Inaki, N; Kinoshita, J; Moriyama, H; Nakamura, K; Okamoto, K; Saito, H; Shimada, M; Tsuji, T; Yamaguchi, T, 2023) |
"We demonstrated in this study that dose escalation using IMRT in combination with platin-based chemotherapy as a definitive treatment for esophageal carcinoma is safe and results in higher loco-regional and control survival when compared to previously reported data." | 1.56 | Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients. ( Carrère, N; Dalmasso, C; Guimbaud, R; Izar, F; Lusque, A; Modesto, A; Moyal, E; Rives, M; Vieillevigne, L, 2020) |
"After 4 weeks, dysphagia scores improved by at least 1 point in 67% of patients in group 1 versus 93% in group 2 (p=0." | 1.40 | Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. ( Archambeaud, I; Landi, B; Lepère, C; Lièvre, A; Mitry, E; Rougier, P; Touchefeu, Y, 2014) |
"Strictures were associated with tumor location (tonsil vs base of tongue; p = ." | 1.37 | Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Ha, PK; Levine, MA; Messing, BP; Murakami, P; Pai, SI; Saunders, JR; Thompson, R; Trachta, J; Ulmer, K; Walker, M; Zinreich, ES, 2011) |
"The palliative effects on dysphagia of radiotherapy (RT) and chemotherapy (CT) were evaluated retrospectively and compared with the effect of the self-expanding stent, evaluated in the prospective study." | 1.29 | Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. ( Albertsson, M; Cwikiel, M; Cwikiel, W, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (18.75) | 18.2507 |
2000's | 3 (18.75) | 29.6817 |
2010's | 8 (50.00) | 24.3611 |
2020's | 2 (12.50) | 2.80 |
Authors | Studies |
---|---|
Yamaguchi, T | 1 |
Okamoto, K | 1 |
Saito, H | 1 |
Shimada, M | 1 |
Tsuji, T | 1 |
Moriyama, H | 1 |
Kinoshita, J | 1 |
Nakamura, K | 3 |
Inaki, N | 1 |
Modesto, A | 1 |
Dalmasso, C | 1 |
Lusque, A | 1 |
Vieillevigne, L | 1 |
Izar, F | 1 |
Moyal, E | 1 |
Carrère, N | 1 |
Guimbaud, R | 1 |
Rives, M | 1 |
Okuno, T | 1 |
Wakabayashi, M | 1 |
Kato, K | 2 |
Shinoda, M | 2 |
Katayama, H | 1 |
Igaki, H | 2 |
Tsubosa, Y | 2 |
Kojima, T | 1 |
Okabe, H | 1 |
Kimura, Y | 1 |
Kawano, T | 1 |
Kosugi, S | 1 |
Toh, Y | 1 |
Kato, H | 1 |
Fukuda, H | 2 |
Ishikura, S | 1 |
Ando, N | 1 |
Kitagawa, Y | 2 |
Kobayashi, T | 1 |
Makino, T | 1 |
Yamasaki, M | 1 |
Tanaka, K | 1 |
Mori, M | 1 |
Doki, Y | 1 |
Touchefeu, Y | 1 |
Archambeaud, I | 1 |
Landi, B | 1 |
Lièvre, A | 1 |
Lepère, C | 1 |
Rougier, P | 1 |
Mitry, E | 1 |
Suh, YG | 1 |
Lee, IJ | 1 |
Koom, WS | 1 |
Cha, J | 1 |
Lee, JY | 1 |
Kim, SK | 1 |
Lee, CG | 1 |
Tsushima, T | 1 |
Mizusawa, J | 1 |
Sudo, K | 1 |
Honma, Y | 1 |
Best, SR | 1 |
Ha, PK | 1 |
Blanco, RG | 1 |
Saunders, JR | 1 |
Zinreich, ES | 1 |
Levine, MA | 1 |
Pai, SI | 1 |
Walker, M | 1 |
Trachta, J | 1 |
Ulmer, K | 1 |
Murakami, P | 1 |
Thompson, R | 1 |
Califano, JA | 1 |
Messing, BP | 1 |
Duman, L | 1 |
Büyükyavuz, BI | 1 |
Altuntas, I | 1 |
Gökcimen, A | 1 |
Ceyhan, L | 1 |
Darici, H | 1 |
Aylak, F | 1 |
Tomruk, O | 1 |
Clavier, JB | 1 |
Antoni, D | 1 |
Atlani, D | 1 |
Ben Abdelghani, M | 1 |
Schumacher, C | 1 |
Dufour, P | 1 |
Kurtz, JE | 1 |
Noel, G | 1 |
Abdel-Wahab, M | 1 |
Abitbol, A | 1 |
Lewin, A | 1 |
Troner, M | 1 |
Hamilton, K | 1 |
Markoe, A | 1 |
Guadagnolo, BA | 1 |
Haddad, RI | 1 |
Posner, MR | 1 |
Weeks, L | 1 |
Wirth, LJ | 1 |
Norris, CM | 1 |
Sullivan, CA | 1 |
Goguen, L | 1 |
Busse, PM | 1 |
Tishler, R | 1 |
Hanazono, K | 1 |
Natsugoe, S | 1 |
Okumura, H | 1 |
Matsumoto, M | 1 |
Oowaki, T | 1 |
Setoyama, T | 1 |
Hiraki, Y | 1 |
Arimura, K | 1 |
Nakamura, F | 1 |
Nakajo, M | 1 |
Aikou, T | 1 |
Burmeister, BH | 1 |
Denham, JW | 1 |
O'Brien, M | 1 |
Jamieson, GG | 1 |
Gill, PG | 1 |
Devitt, P | 1 |
Yeoh, E | 1 |
Hamilton, CS | 1 |
Ackland, SP | 1 |
Lamb, DS | 1 |
Cwikiel, M | 1 |
Cwikiel, W | 1 |
Albertsson, M | 1 |
Kuvshinov, IuP | 1 |
Poddubnyĭ, BK | 1 |
Aliev, VM | 1 |
Vasygova, NF | 1 |
Efimov, ON | 1 |
Khydyrov, KhB | 1 |
Saliuk, VA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma, an Open, Prospective, Single-arm Phase II Study[NCT04212598] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-08-03 | Recruiting | ||
Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480] | Phase 2 | 63 participants (Actual) | Interventional | 2020-02-01 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
Intervention | biomarkers (Number) |
---|---|
Reduced Dose Radiation | 0 |
Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
Intervention | score on a scale (Mean) |
---|---|
Reduced Dose Radiation | -8.12 |
Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
Intervention | score on a scale (Mean) |
---|---|
Reduced Dose Radiation | 2.18 |
Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
Intervention | Participants (Count of Participants) |
---|---|
Reduced Dose Radiation | 3 |
Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
Intervention | Participants (Count of Participants) |
---|---|
Reduced Dose Radiation | 10 |
Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
Intervention | Participants (Count of Participants) |
---|---|
Reduced Dose Radiation | 10 |
Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
Intervention | score on a scale (Mean) | |||
---|---|---|---|---|
EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
Intervention | score on a scale (Mean) | |
---|---|---|
MDASI-HN SI | MDASI-HN SS | |
Reduced Dose Radiation | 0.64 | 0.52 |
Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
Intervention | Participants (Count of Participants) | |
---|---|---|
at 3 years | at 5 years | |
Reduced Dose Radiation | 10 | 10 |
Standard Dose Radiation | 7 | 7 |
5 trials available for fluorouracil and Esophageal Stenosis
Article | Year |
---|---|
Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Squamous | 2017 |
Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2005 |
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2005 |
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aust | 1995 |
11 other studies available for fluorouracil and Esophageal Stenosis
Article | Year |
---|---|
Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis.
Topics: Cisplatin; Constriction, Pathologic; Deglutition Disorders; Docetaxel; Esophageal Stenosis; Fluorour | 2023 |
Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2020 |
Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2019 |
Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
The efficacy of single-dose 5-fluorouracil therapy in experimental caustic esophageal burn.
Topics: Animals; Burns, Chemical; Caustics; Cell Differentiation; Cell Division; Cicatrix; Drug Evaluation, | 2011 |
Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
[An effective treatment by chemoradiation therapy after stent insertion for advanced esophageal cancer with esophago-pulmonary fistula--report of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1996 |
[Endoscopic laser recanalization in the chemo- and radiotherapy of stenosing cancer of the esophagus].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Esophageal Neoplasms; Esophageal | 1990 |